Ibrance cleared in US for 'double-positive' breast cancer

Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.

FDA removes leash from Verzenio in early breast cancer

Drug can now be used as adjuvant therapy without Ki-67 testing, taking a brake off prescribing.

Routine NHS access to Ibrance assured with new NICE guidance

Thousands of patients with a particular form of breast cancer in England and Wales can be confident they will continue to have access to Pfizer's targeted therapy Ibrance, thanks to new gui

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s

NICE backs Ibrance for breast cancer via Cancer Drugs Fund

Scotland backs Pfizer’s Ibrance for breast cancer